Form 4: Sarepta Therapeutics Executive Dallan Murray Sells Shares Under 10b5-1 Trading Plan

Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, sold 3,635 shares of common stock at $140 per share on May 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 2, 2024, Dallan Murray, the Chief Customer Officer of Sarepta Therapeutics, sold 3,635 shares of the company's common stock.
• The sale was executed at a price of $140 per share.
• Following the transaction, Murray directly owns 18,125 shares of Sarepta Therapeutics.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 15, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was conducted under a pre-arranged trading plan, suggesting it's not necessarily indicative of the executive's view on the company's future prospects.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Rule 10b5-1 trading plans allow insiders to sell shares at predetermined times and prices to avoid accusations of insider trading. The market will often look at the ratio of buys to sells by insiders to determine sentiment.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates